Tedros Adhanom Ghebreyesus & Serum Institute of India

Tedros Adhanom Ghebreyesus: WHO Director-General, making multiple visits to DRC, urging scale-up and warning the outbreak is outpacing response. His leadership is central to global health response.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, has been instrumental in declaring the public health emergency and communicating the escalating risk of the Ebola outbreak.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced the six-month plan to fight Ebola and called for political commitment and funding.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.

Tedros Adhanom Ghebreyesus: As WHO Director-General, he declared the outbreak a global emergency, raising international awareness and mobilizing resources.

Serum Institute of India: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus>>>, the Director-General of the World Health Organization>>>, has declared the Ebola outbreak a public health emergency of international concern and is actively involved in coordinating the response, visiting affected areas and urging international action.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.